

Supplementary Figure 6. TM4SF1 inhibits senescence *in vivo* and regulates PD-L1 and MHC I expression in HCC cells. (A) Expression of *Tm4sf1* in different HCC models. (B) Expression of *Tm4sf1*, *Cdkn1a*, and *Cdkn2a* in different groups (n=5). (C) Changes of Ki-67 index, p-AKT-S473, p16 and p21 in HTVi model, based on IHC staining (n=5). (D) PD-L1 and MHC I expression level in HLF on the basis of TM4SF1 knockdown or overexpression, under control (PBS) or IFN-γ stimulation (40 ng/mL, 24 hours). (E) PD-L1 and MHC I expression level in IFN-γ stimulated HLF (40 ng/mL, 24 hours) with AKT1 supplementation following TM4SF1 knockdown. Data are represented as means±standard deviation. *P*-values were calculated using the Student's *t*-test (unpaired). ns>0.05, **P*<0.05, ***P*<0.01, ****P*<0.001, *****P*<0.0001. TM4SF1, transmembrane 4 L six family member 1; PD-L1, programmed cell death ligand 1; MHC I, major histocompatibility complex class I; HCC, hepatocellular carcinoma; HTVi, hydrodynamic tail vein injection; IFN-γ, interferon gamma; ns, not significant.